Valneva (VALN) has released an update.
Valneava and Pfizer have announced the completion of the primary vaccination series for their Phase 3 VALOR Lyme disease vaccine trial with VLA15. The trial, which targets the prevention of the most common vector-borne illness in the Northern Hemisphere, will see participants monitored for Lyme disease cases until the end of 2025. Positive trial results could lead to regulatory submissions for the vaccine in the U.S. and Europe by 2026.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
